Diagnosis of prostate cancer (PCa) and adequate staging play a fundamental role for
clinical and patient care. Despite major advances in biology and imaging, rectal examination …

Early detection of prostate cancer (PC) is largely carried out using assessment of prostate-
specific antigen (PSA) level; yet it cannot reliably discriminate between benign pathologies …

Importance Overdiagnosis and overtreatment of indolent prostate cancer (PCA) is a serious
health issue in most developed countries. There is an unmet clinical need for noninvasive …

Background Discriminating indolent from clinically significant prostate cancer (PCa) in the
initial biopsy setting remains an important issue. Prospectively evaluated diagnostic assays …

Background To reduce overdiagnosis and overtreatment, a test is urgently needed to detect
clinically significant prostate cancer (PCa). Objective To develop a multimodal model …

Background The prostate-specific antigen (PSA) test is used to screen for prostate cancer
but has a high false-positive rate that translates into unnecessary prostate biopsies and …

Background Screening for prostate cancer using prostate-specific antigen (PSA) alone leads
to un-necessary biopsying and overdiagnosis. PSA density is easily accessible, but early …

Following detection of high levels of serum prostate-specific antigen, many men are advised
to have transrectal ultrasound-guided biopsy in an attempt to locate a cancer. This …

Solid cancers are one of the leading causes of cancer related deaths, characterized by rapid
growth of tumour, and local and distant metastases. Current advances on multimodality care …

Purpose In 2012, the US Preventive Services Task Force (USPSTF) discouraged prostate-
specific antigen (PSA)–based prostate cancer screening. Previous USPSTF …